Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 4/20 | 0.44 |
| ▸ | AXL | P30530 | 2/20 | 0.44 |
| ▸ | JAK1 | P23458 | 8/20 | 0.41 |
| ▸ | JAK2 | O60674 | 8/20 | 0.40 |
| ▸ | JAK3 | P52333 | 3/20 | 0.40 |
| ▸ | KDR | P35968 | 3/20 | 0.40 |
| ▸ | AURKA | O14965 | 2/20 | 0.40 |
| ▸ | PRKCA | P17252 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | NUDT1 | P36639 | 3/20 | 0.38 |
| ▸ | RET | P07949 | 2/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.38 |
| ▸ | LTK | P29376 | 2/20 | 0.38 |
| ▸ | GRK5 | P34947 | 2/20 | 0.38 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | STK33 | Q9BYT3 | 1/20 | 0.38 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | CHUK | O15111 | 1/20 | 0.36 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17353634 | 0.78 | PRKCI (0.42) | PRKCIAXLJAK1JAK2JAK3 | |
| SCHEMBL30846798 | 0.75 | KDM4A (0.37) | RPS6KA3 | |
| SCHEMBL1933750 | 0.74 | PRKCI (0.42) | PRKCIAXLJAK1JAK2JAK3 | |
| SCHEMBL19743086 | 0.73 | PRKCI (0.41) | PRKCIAXLJAK1JAK2JAK3 | |
| SCHEMBL4352565 | 0.72 | NUDT1 (0.47) | PRKCIAXLJAK1JAK2JAK3 | |
| SCHEMBL20289774 | 0.72 | JAK3 (0.41) | PRKCIAXLJAK1JAK2JAK3 | |
| SCHEMBL12424590 | 0.72 | PRKCI (0.47) | PRKCIAXLJAK1JAK2JAK3 | |
| SCHEMBL29588119 | 0.72 | PRKCI (0.47) | PRKCIAXLJAK1JAK2JAK3 | |
| SCHEMBL28735162 | 0.72 | PRKCI (0.40) | PRKCIAXLJAK1JAK2JAK3 | |
| SCHEMBL202156 | 0.71 | PDPK1 (0.55) | JAK2ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10266532-B2 | Tricyclic modulators of TNF signaling | ABBVIE INC. (US) | 2019-04-23 | — | — | US | claimed |
| WO-2023248010-A3 | TARGETED MODULATORS OF JAK3 FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | SYNOVO GMBH (DE) | 2024-03-07 | — | — | WO | disclosed |
| WO-2023248010-A2 | TARGETED MODULATORS OF JAK3 FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | SYNOVO GMBH (DE) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023248010-A2 | TARGETED MODULATORS OF JAK3 FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | SYNOVO GMBH (DE) | 2023-12-28 | — | — | WO | disclosed |
| US-20230374011-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS | UNICHEM LABORATORIES LTD. (IN) | 2023-11-23 | — | — | US | disclosed |
| US-20230374011-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS | UNICHEM LABORATORIES LTD. (IN) | 2023-11-23 | — | — | US | disclosed |
| US-20230374011-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS | UNICHEM LABORATORIES LTD. (IN) | 2023-11-23 | — | — | US | disclosed |
| US-20230364135-A1 | GUT-SELECTIVE SEQUESTERING AGENTS FOR THE TREATMENT AND PREVENTION OF AUTISM AND RELATED DISORDERS | AXIAL BIOTHERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| WO-2023154966-A1 | COMPOSITIONS AND METHODS FOR SEQUESTERING METABOLITES IN THE GASTROINTESTINAL TRACT | AXIAL THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| EP-4225442-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS | Unichem Laboratories Ltd (IN) | 2023-08-16 | — | — | EP | disclosed |
| US-20100210629-A1 | 1,6-DIHYDRO-1,3,5,6-TETRAAZA-AS-INDACENE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-19 | — | — | US | disclosed |
| US-7737279-B2 | 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-15 | — | — | US | disclosed |
| US-7737279-B2 | 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-15 | — | — | US | disclosed |
| EP-1888584-B1 | 1, 6 -DIHYDRO- 1,3, 5, 6-TETRAAZA-AS-INDACENE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME AS INHIBITORS OF IKK ENZYME ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2010-04-21 | — | — | EP | disclosed |
| EP-1888584-B1 | 1, 6 -DIHYDRO- 1,3, 5, 6-TETRAAZA-AS-INDACENE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME AS INHIBITORS OF IKK ENZYME ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2010-04-21 | — | — | EP | disclosed |
| EP-1888584-A1 | 1, 6 -DIHYDRO- 1,3, 5, 6-TETRAAZA-AS-INDACENE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME AS INHIBITORS OF IKK ENZYME ACTIVITY | Brystol-Myers Squibb Company (US) | 2008-02-20 | — | — | EP | disclosed |
| US-20070191420-A1 | Kinase inhibitors | DEVGEN NV | 2007-08-16 | — | — | US | disclosed |
| US-20060270654-A1 | 1,6-Dihydro-1,3,5,6-Tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY | 2006-11-30 | — | — | US | disclosed |
| US-20060270654-A1 | 1,6-Dihydro-1,3,5,6-Tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY | 2006-11-30 | — | — | US | disclosed |
| WO-2006122137-A1 | 1, 6 -DIHYDRO- 1,3, 5, 6-TETRAAZA-AS-INDACENE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME AS INHIBITORS OF IKK ENZYME ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210629-A1 | 1,6-DIHYDRO-1,3,5,6-TETRAAZA-AS-INDACENE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | IL1R1, IDO1, TLR1 | PRKCI 4110/4885AXL 4116/4885JAK1 500/4885 |
| US-20230374011-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS | CCNY, CNKSR1, CDK1 | PRKCI 491/4885AXL 2280/4885JAK1 432/4885 |
| US-20060270654-A1 | 1,6-Dihydro-1,3,5,6-Tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same | IL1R1, IDO1, TLR1 | PRKCI 4110/4885AXL 4116/4885JAK1 500/4885 |
| US-20070191420-A1 | Kinase inhibitors | ROCK1, ROCK2, MAP3K20 | PRKCI 113/4885AXL 673/4885JAK1 86/4885 |
| US-10266532-B2 | Tricyclic modulators of TNF signaling | TNF, TNFRSF1A, CD40 | PRKCI 668/4885AXL 1101/4885JAK1 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.